{"id":3873,"date":"2016-10-12T10:45:00","date_gmt":"2016-10-12T08:45:00","guid":{"rendered":"https:\/\/ibtherapeutics.com\/sv\/mfn_news\/infant-bacterial-therapeutics-ab-utser-ny-finansdirektor-cfo\/"},"modified":"2023-10-02T13:51:48","modified_gmt":"2023-10-02T11:51:48","slug":"infant-bacterial-therapeutics-ab-utser-ny-finansdirektor-cfo","status":"publish","type":"mfn_news","link":"https:\/\/ibtherapeutics.com\/sv\/pressmeddelanden\/infant-bacterial-therapeutics-ab-utser-ny-finansdirektor-cfo\/","title":{"rendered":"Infant Bacterial Therapeutics AB utser ny Finansdirekt\u00f6r (CFO)"},"content":{"rendered":"<div class=\"mfn-preamble\">Infant Bacterial Therapeutics AB (publ.) (&#8220;IBT&#8221;) har n\u00f6jet att tillk\u00e4nnage utn\u00e4mningen av Daniel Mackey som Finansdirekt\u00f6r (Chief Financial Officer) med tilltr\u00e4de i januari 2017. Daniel ers\u00e4tter Michael Owens i denna roll. Michael Owens forts\u00e4tter som controller f\u00f6r f\u00f6retaget.<\/div>\n<p>Daniel har 20 \u00e5rs erfarenhet av olika amerikanska och internationella ledande befattningar inom ekonomi och redovisning i Investors Bank &amp; Trust Co, Nordea Investment Management AB och Nordea Bank AB. I sin roll som CFO kommer Daniel bland annat att ansvara f\u00f6r f\u00f6retagets kapital- och finansieringsstrategier, redovisning och investerarrelationer.<\/p>\n<p>&#8211; Vi v\u00e4lkomnar Daniel till IBT. V\u00e5rt nuvarande fokus ligger p\u00e5 den p\u00e5g\u00e5ende amerikanska kliniska pr\u00f6vningen i fas II. N\u00e4sta \u00e5r kommer inneb\u00e4ra nya stora utmaningar och vi \u00e4r d\u00e4rf\u00f6r mycket glada \u00f6ver att ha Daniel ombord s\u00e5 att han kan bidra till utvecklingen av IBT, s\u00e4ger IBT:s VD Staffan Str\u00f6mberg.<\/p>\n<p>Mer information om vilka som jobbar p\u00e5 IBT finns p\u00e5 IBT:s hemsida <a href=\"http:\/\/ibtherapeutics.com\/about-ibt\/the-team\/\" rel=\"nofollow\">http:\/\/ibtherapeutics.com\/about-ibt\/the-team\/<\/a><\/p>\n<p>F\u00f6r mer information, v\u00e4nligen kontakta<\/p>\n<p>Staffan Str\u00f6mberg, VD, telefon: +46 8 410 145 55<\/p>\n<p>Infant Bacterial Therapeutics AB<\/p>\n<p>Bryggargatan 10<\/p>\n<p>111 21 Stockholm<\/p>\n<p>Telefon: +46 8 410 145 55<\/p>\n<p>info@ibtherapeutics.com\u00a0<\/p>\n<div class=\"mfn-footer\"><\/div>\n<script>\n                Array.prototype.slice.call(document.querySelectorAll(\".mfn-footer.mfn-attachment\")).forEach(function (el) { el.remove() });\n            <\/script>\n        <div class=\"mfn-attachments-container\"><div class=\"mfn-attachment\"><a class=\"mfn-attachment-link\" href=\"https:\/\/storage.mfn.se\/proxy\/pdf.pdf?url=http%3A%2F%2Fmb.cision.com%2FMain%2F14085%2F2099417%2F573712.pdf\"><span class=\"mfn-attachment-icon\"><img alt=\"Infant Bacterial Therapeutics AB utser ny Finansdirekt\u00f6r (CFO)\" src=\"https:\/\/storage.mfn.se\/proxy\/pdf.pdf?url=http%3A%2F%2Fmb.cision.com%2FMain%2F14085%2F2099417%2F573712.pdf&type=jpg\"><\/span>PDF<\/a><\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>Infant Bacterial Therapeutics AB (publ.) (&#8220;IBT&#8221;) har n\u00f6jet att tillk\u00e4nnage utn\u00e4mningen av Daniel Mackey som Finansdirekt\u00f6r (Chief Financial Officer) med tilltr\u00e4de i januari 2017. Daniel ers\u00e4tter Michael Owens i denna roll. Michael Owens forts\u00e4tter som controller f\u00f6r f\u00f6retaget. Daniel har 20 \u00e5rs erfarenhet av olika amerikanska och internationella ledande befattningar inom ekonomi och redovisning i [&hellip;]<\/p>\n","protected":false},"template":"","_links":{"self":[{"href":"https:\/\/ibtherapeutics.com\/sv\/wp-json\/wp\/v2\/mfn_news\/3873"}],"collection":[{"href":"https:\/\/ibtherapeutics.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/ibtherapeutics.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/ibtherapeutics.com\/sv\/wp-json\/wp\/v2\/media?parent=3873"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}